Lupin Pharma Canada Ltd. announced the launch of Propranolol LA (long-acting) capsules,60 mg, 80 mg, 120 mg and 160 mg, in Canada. A generic equivalent of Inderal® LA, Propranolol LA provides an effective treatment solution since the discontinuation of Inderal® LA for patients and healthcare practitioners. Propranolol LA's launch caters to the needs of Canadian patients,reaffirming Lupin's commitment to enhancing healthcare access and affordability.

"We are delighted to announce the launch of Propranolol LA capsules for patients in Canada. We have diligently worked to build our portfolio to include Propranolol LA ensuring patients have access to the essential medicines. This launch signifies our commitment to fostering healthcare solutions that truly make a difference,"said Dr. Sofia Mumtaz, President – Legal, Canada, Australia, and Japan, Lupin.